In this post, we discuss therapeutic antibodies and biosimilars and the need for biosimilar comparability analysis and characterization, with a focus on methods for assessing structural comparability.
Using an integrated drug discovery approach, first-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
This post provides the latest company news update. It would be fair to keep our former clients, followers, and anybody…
What makes a successful services company? What is our strength, and how to define our selling points? We arrive at a list of 8 essential selling points defining the success of SARomics Biostructures.
In this third post on structural biology and structure-based drug design we discuss methods and benefits of fragment-based lead discovery
A pleasant surprise! A paper describing the interaction of the therapeutic peptide dusquetide with the ZZ domain of the autophagic receptor p62 was published around 12 years after the structure was solved!
Several private and public organizations join efforts in the LundaGUARD consortium to respond to present and future threats from infectious agents.
Since our first trip into the realm of EU projects with the KINOMED project, we have now engaged in seven…
SARomics Biostructures is continuing its expansion with new team members, an updated company logotype, expanded laboratory and office space, and…
It was a fantastic year for the company! We introduced new team members and new services, including WAC fragment screening…